Compare DDD & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | SENS |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Industrial Machinery/Components |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.2M | 301.2M |
| IPO Year | 2003 | 2014 |
| Metric | DDD | SENS |
|---|---|---|
| Price | $2.78 | $5.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.75 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 3.4M | 853.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $386,902,000.00 | $16,389,000.00 |
| Revenue This Year | $2.48 | $74.15 |
| Revenue Next Year | $4.10 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $1.57 | $0.41 |
| 52 Week High | $4.12 | $8.75 |
| Indicator | DDD | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 35.99 |
| Support Level | $2.69 | $4.79 |
| Resistance Level | $2.89 | $5.94 |
| Average True Range (ATR) | 0.18 | 0.31 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 22.43 | 15.24 |
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.